We barcoded two treatment-sensitive ER+ breast cancer cell lines and then rendered them resistant to Tamoxifen (TAMR) or long-term estrogen deprivation (LTED), the latter mimicking clinically applied aromatase inhibition. Here, ESR1 is linked to breast cancer.